ECM
ACOR

ExodusPoint Capital Management’s Acorda Therapeutics ACOR Stock Holding History

ExodusPoint Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-128
Closed -$11K – 2359
2020
Q2 		$11K Buy
+128
New +$13.5K ﹤0.01% 1719

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ExodusPoint Capital Management's ACOR Position: Q3 2020 in Review

ExodusPoint Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 128 shares — an estimated $11K sold.

ExodusPoint Capital Management first reported a position in ACOR in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • ExodusPoint Capital Management reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • ExodusPoint Capital Management sold 128 Acorda Therapeutics shares in Q3 2020, an estimated $11K.
  • ExodusPoint Capital Management first reported a position in Acorda Therapeutics in Q2 2020 and held it in 1 quarter.
  • ExodusPoint Capital Management's Acorda Therapeutics position peaked at $11K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.